Skip to main
OPK

OPKO Health (OPK) Stock Forecast & Price Target

OPKO Health (OPK) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

OPKO Health Inc. has reported a notable 5.3% volume growth in the non-oncology lab business, alongside a significant 20% increase in 4Kscore test volumes, indicating a strong demand for its diagnostic offerings. The company's BARDA-related revenue rose to $8.2 million, marking an improvement from $5.5 million in the prior year, suggesting enhanced performance in its pharmaceutical segment. Overall, the anticipated margin improvements in diagnostics, combined with effective cost-saving initiatives and a promising outlook for the 4Kscore diagnostic product, bolster a favorable financial perspective for OPKO Health.

Bears say

OPKO Health Inc. faced a significant operating loss of $18.3 million in its diagnostics segment during the recent quarter, contributing to a broader negative financial outlook. Additionally, the company's pharmaceutical product revenue declined to $37.7 million, down from $39.1 million the previous year, primarily due to lower sales volumes attributed to unfavorable customer timing and product mix. The disappointing financial guidance for FY/26, paired with a top-line revenue miss and increasing operating expenses, further supports the negative sentiment surrounding the company's stock.

OPKO Health (OPK) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About OPKO Health (OPK) Forecast

Analysts have given OPKO Health (OPK) a Buy based on their latest research and market trends.

According to 3 analysts, OPKO Health (OPK) has a Buy consensus rating as of Mar 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.03, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.03, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

OPKO Health (OPK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.